{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:32:17Z","timestamp":1790645537675,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ahj.2013.08.007","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T14:45:19Z","timestamp":1380811519000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension"],"prefix":"10.1016","volume":"167","clinical-trial-number":[{"clinical-trial-number":"nct01431716","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Olivier","family":"Sitbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bergot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anco B.","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Granton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Escribano","family":"Sub\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lemari\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.08.007_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2013.08.007_bb0010","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gali\u00e8","year":"2009","journal-title":"Eur Respir J"},{"issue":"1 Suppl","key":"10.1016\/j.ahj.2013.08.007_bb0020","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.08.007_bb0025","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/17425255.2010.534458","article-title":"Pharmacokinetic evaluation of continuous intravenous epoprostenol","volume":"6","author":"Chaumais","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ahj.2013.08.007_bb0030","unstructured":"Flolan\u00ae US prescribing information. http:\/\/us.gsk.com\/products\/assets\/us_flolan.pdf."},{"key":"10.1016\/j.ahj.2013.08.007_bb0035","unstructured":"Flolan\u00ae EMA Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/flolan_30\/WC500129816.pdf."},{"key":"10.1016\/j.ahj.2013.08.007_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DDDT.S29916","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ahj.2013.08.007_bb0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/DDDT.S31628","article-title":"Stability and preservation effectiveness of a new formulation of epoprostenol sodium for the treatment of pulmonary arterial hypertension","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ahj.2013.08.007_bb0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clinthera.2013.02.013","article-title":"Comparative pharmacokinetics, pharmacodynamics, and tolerability of three different formulations of epoprostenol sodium for injection in healthy male subjects","volume":"35","author":"Nicolas","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2013.08.007_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated treatment satisfaction questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ahj.2013.08.007_bb0060","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2013.08.007_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2013.08.007_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1742-1241.2010.02525.x","article-title":"How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?","volume":"64","author":"Barst","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ahj.2013.08.007_bb0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ahj.2013.08.007_bb0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":"Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","volume":"129","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2013.08.007_bb0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjcard.2006.02.061","article-title":"N-terminal pro\u2013B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension","volume":"98","author":"Andreassen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2013.08.007_bb0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mayocp.2012.05.014","article-title":"Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY\u00ae","volume":"87","author":"Kitterman","year":"2012","journal-title":"Mayo Clin Proc"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313005310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870313005310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:50:46Z","timestamp":1757569846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870313005310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0002870313005310"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.08.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}